ASH 2022 | ASH 2022 LBA: Results from final analysis of ALPINE – zanubrutinib vs ibrutinib for R/R CLL/SLL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, shares the final results of the randomized Phase III ALPINE study (NCT03734016) which compared zanubrutinib with ibrutinib as treatment for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), explaining that the trial demonstrated a progression-free survival (PFS) advantage for zanubrutinib, and commenting on the implications of these results on clinical practice. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The ALPINE study is a randomized study comparing zanubrutinib to ibrutinib in patients with relapsed CLL. As a late breaking abstract, we’ll see the data looking at, for the first time, progression-free survival advantage of zanubrutinib compared to ibrutinib, and also the improved safety profile, which we already knew from the interim analysis.
For clinical practice now with different therapeutic options for physicians and patients, it’s important to have head-to-head randomized trial data, in addition to some of the intolerance studies that we had...
The ALPINE study is a randomized study comparing zanubrutinib to ibrutinib in patients with relapsed CLL. As a late breaking abstract, we’ll see the data looking at, for the first time, progression-free survival advantage of zanubrutinib compared to ibrutinib, and also the improved safety profile, which we already knew from the interim analysis.
For clinical practice now with different therapeutic options for physicians and patients, it’s important to have head-to-head randomized trial data, in addition to some of the intolerance studies that we had. Really the discussion with the patient may lead to selecting better-tolerated next-generation BTK inhibitors.
I think ALPINE will be important, especially with the data showing an improved progression-free survival, which is shown for the first time in CLL, can potentially change the treatment landscape for some of the CLL patients.
Read more...
Disclosures
AbbVie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Sound Biologics: Consultancy; Pharmacyclics: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Morphosys/Incyte: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Innate Pharma: Consultancy; Kite Pharma: Consultancy; Adaptive Biotechnologie: Consultancy; Epizyme: Consultancy; Eli Lilly: Consultancy; Adaptimmune: Consultancy; Mustang Bio: Consultancy, Research Funding; Regeneron: Consultancy; Merck: Consultancy; Fate Therapeutics: Consultancy; MEI Pharma: Consultancy; Atara Biotherapeutic: Consultancy, Research Funding; Celgene: Research Funding; Gilead: Research Funding; Sunesis: Research Funding; Genmab: Research Funding.
